20 July 2022 - - US-based life sciences company Labcorp (NYSE: LH) has expanded its automated clinical trial kit production line in Mechelen, Belgium, the company said.

Once completed, expansion will allow for clinical trial test kits to be fulfilled in Mechelen for more than 70 countries throughout Europe, the Middle East and Africa.

This is up from 27 countries in 2021. The company's industry-leading central laboratory services unit is part of Labcorp Drug Development.

The expanded, automated line is housed in Labcorp Drug Development's European Operations Center, a multi-use facility responsible for kit production as well as study logistics and support and dry ice production and distribution.

Since opening in March 2021, this site has produced more than 1.1m trial kits for clinical research across Europe in support of studies in oncology, diabetes, kidney disease and autoimmune conditions.

Kit production follows the same global standard operating procedures across Europe and the United States, so sponsors and investigators will continue to receive the specimen collection kits they already associate with Labcorp Central Laboratory Services regardless of where they are produced.

The expansion of the facility in Mechelen follows the recent expansions of Labcorp Drug Development's Central Laboratories in Geneva, Switzerland, Los Angeles and Singapore, providing enhanced support for global clinical trials.

Labcorp is a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.

Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives.

With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of USD 16bn in FY2021.